P.BantayanN.et al (2024)
Safety Profile: What We Learned About Side Effects Common Adverse Events The TRIUMPH-4 trial confirmed that retatrutide's side effect profile aligns with other incretin-based therapies, with gastrointestinal symptoms being the most common: Incidence of GI Side Effects (12mg dose): Nausea: 43% (vs 11% placebo) Diarrhea: 33% (vs 13% placebo) Vomiting: 21% (vs 0% placebo) Constipation: Elevated vs placebo Decreased appetite: Common Most gastrointestinal side effects were mild to moderate in severity and occurred primarily during the dose escalation phase
It starts working after being absorbed and continues to have an effect for a long time, which makes it convenient for once-daily dosing
Glutathione helps protect brain cells from oxidative damage, potentially slowing down cognitive decline and promoting better brain health
Your starting tirzepatide dose is based on your current semaglutide dose, tolerability, and weight loss response
Diabetes coverage often requires a simple prior authorization confirming diagnosis, while weight-management coverage may require documented BMI, comorbidities, or failed prior treatments